CAR-T Long Term Follow Up (LTFU) Study
Launched by NOVARTIS PHARMACEUTICALS · May 12, 2015
Trial Information
Current as of June 06, 2025
Recruiting
Keywords
ClinConnect Summary
The CAR-T Long Term Follow Up Study is designed to check on the long-term safety and effectiveness of patients who have received CAR-T therapy, a type of treatment that uses genetically modified cells to fight certain cancers. This study will follow patients for 15 years after their last CAR-T treatment to look for any delayed side effects and to understand how well the therapy continues to work over time. It's important because health authorities want to ensure that patients are monitored for any potential risks associated with this innovative treatment.
To be eligible for this study, participants must have previously received CAR-T therapy through specific clinical trials sponsored by Novartis or the University of Pennsylvania. If you decide to participate, you can expect regular check-ins over the years to track your health, any side effects, and the overall success of the treatment. There are no specific exclusions for this study, so anyone who meets the inclusion criteria and gives their consent can join. This is a great opportunity to contribute to our understanding of CAR-T therapy and help improve future treatment for others.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients who have received a CAR-T therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CAR-T cells or from any CAR-T trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology.
- • Patients who have provided informed consent for the long term follow up study prior to their study participation .
- Exclusion Criteria:
- • There are no specific exclusion criteria for this study.
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Minneapolis, Minnesota, United States
Boston, Massachusetts, United States
Philadelphia, Pennsylvania, United States
Cincinnati, Ohio, United States
Los Angeles, California, United States
Boston, Massachusetts, United States
Madison, Wisconsin, United States
Los Angeles, California, United States
Portland, Oregon, United States
Ulm, , Germany
Birmingham, , United Kingdom
San Francisco, California, United States
Montreal, Quebec, Canada
Pierre Benite Cedex, , France
Frankfurt Am Main, Hessen, Germany
Berlin, , Germany
Hamburg, , Germany
Leipzig, , Germany
Bologna, Bo, Italy
Monza, Mb, Italy
Singapore, , Singapore
Hospitalet De Llobregat, Catalunya, Spain
London, , United Kingdom
Atlanta, Georgia, United States
Milano, Mi, Italy
Camperdown, New South Wales, Australia
Parkville, Victoria, Australia
Villejuif, , France
Regensburg, Bavaria, Germany
Oslo, , Norway
Barcelona, Catalunya, Spain
Taipei, , Taiwan
Vienna, , Austria
Hong Kong, , Hong Kong
New York, New York, United States
Salzburg, , Austria
Vienna, , Austria
Gent, , Belgium
Copenhagen, , Denmark
Milano, Mi, Italy
Sevilla, Andalucia, Spain
Paris Cedex 10, , France
New York, New York, United States
Phoenix, Arizona, United States
Wien, , Austria
Frankfurt, , Germany
Ramat Gan, , Israel
Amsterdam, , Netherlands
Detroit, Michigan, United States
Muenchen, , Germany
Copenhagen, , Denmark
Paris Cedex 19, , France
Stanford, California, United States
Koeln, , Germany
Sapporo City, Hokkaido, Japan
Chuo Ku, Tokyo, Japan
Salamanca, Castilla Y Leon, Spain
Valencia, Comunidad Valenciana, Spain
Wuerzburg, , Germany
Oslo, , Norway
Rozzano, Mi, Italy
Toronto, Ontario, Canada
Linz, , Austria
Seoul, , Korea, Republic Of
Leipzig, Sachsen, Germany
Pierre Benite, , France
Pamplona, Navarra, Spain
Helsinki, , Finland
Roma, Rm, Italy
Esplugues De Llobregat, Barcelona, Spain
Madrid, , Spain
Ramat Gan, , Israel
Tel Aviv, , Israel
Fukuoka City, Fukuoka, Japan
Paris, , France
Nantes, , France
Ann Arbor, Michigan, United States
Melbourne, Victoria, Australia
Wien, , Austria
Sendai City, Miyagi, Japan
Murdoch, Western Australia, Australia
Utrecht, Cs, Netherlands
Los Angeles, California, United States
Atlanta, Georgia, United States
Philadelphia, Pennsylvania, United States
Kyoto, , Japan
Duarte, California, United States
Phoenix, Arizona, United States
Stanford, California, United States
Chicago, Illinois, United States
Westwood, Kansas, United States
Ann Arbor, Michigan, United States
Minneapolis, Minnesota, United States
Kansas City, Missouri, United States
Durham, North Carolina, United States
Columbus, Ohio, United States
Dallas, Texas, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Camperdown, , Australia
Hamilton, Ontario, Canada
Atlanta, Georgia, United States
Boston, Massachusetts, United States
San Francisco, California, United States
Ann Arbor, Michigan, United States
Boston, Massachusetts, United States
Vienna, , Austria
Paris 10, , France
Stanford, California, United States
Atlanta, Georgia, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Herston, , Australia
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials